MedWatch

Novo stops bleeding in hemophilia business and aims for growth in 2020

After a sharp decline in sales in 2017, sales of Novo Nordisk's hemophilia drugs and growth hormones remained largely stable last year. CEO Lars Fruergaard Jørgensen expects the sales to increase again within a few years.

Foto: /Ritzau Scanpix/Asger Ladefoged/

Though Novo Nordisk's insulin sales decreased in 2018, the Danish drug group seems to have stopped the bleeding in its Biopharm business that includes growth hormones and hemophilia drugs.

In 2017, the Biopharm sales decreased by 16 percent in local currencies, but in 2018 the decline shrank to one percent. According to CEO in Novo Nordisk, Lars Fruergaard Jørgensen, the results will improve in the years to come.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier